Related Experiment Video
Updated: Sep 14, 2025

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
Published on: November 5, 2014
Parp7 generates an ADP-ribosyl degron that controls negative feedback of androgen signaling
Krzysztof Wierbiłowicz1,2, Chun-Song Yang1, Ahmed Almaghasilah3
1Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, PO Box 800733, Charlottesville, VA, 22908, USA.
Abstract:
The androgen receptor (AR) transduces the effects of circulating and tumor-derived androgens to the nucleus through ligand-induced changes in protein conformation, localization, and chromatin engagement. Defining how these events are integrated with signal transduction is critical to understand how AR drives prostate cancer and unveil pathway features that are potentially amenable to therapeutic intervention. We describe a novel post-transcriptional mechanism that controls AR levels on chromatin and gene output based on highly selective, inducible degradation. We find that the mono-ADP-ribosyltransferase PARP7 generates an ADP-ribosyl degron in the DNA-binding domain of AR, which is recognized by the ADP-ribose reader domain in the ubiquitin E3 ligase DTX2 and degraded by the proteasome. Mathematical modeling of the pathway suggested that PARP7 ADP-ribosylates chromatin-bound AR, a prediction that was validated in cells using an AR DNA-binding mutant. Non-conventional ubiquitin conjugation to ADP-ribosyl-cysteine and degradation by the proteasome forms the basis of a negative feedback loop that regulates modules of AR target genes. Our data expand the repertoire of mono-ADP-ribosyltransferases to include gene regulation via highly selective protein degradation.
Insights
Scientists discovered a new way to control androgen receptor (AR) levels in prostate cancer cells. A protein called PARP7 tags AR for degradation, offering potential new therapeutic targets.
Area of Science:
- Molecular Biology
- Cancer Research
- Biochemistry
Background:
- Androgen receptor (AR) signaling is crucial for prostate cancer development.
- Understanding AR regulation is key for developing effective cancer therapies.
Purpose of the Study:
- To elucidate a novel post-transcriptional mechanism controlling AR levels and activity.
- To identify new therapeutic targets for prostate cancer by understanding AR regulation.
Main Methods:
- Investigated the role of PARP7 and DTX2 in AR regulation.
- Utilized mathematical modeling to predict pathway dynamics.
- Employed AR DNA-binding mutants to validate findings in cellular models.
Main Results:
- Identified a novel pathway where PARP7 creates an ADP-ribosyl degron on AR.
- DTX2 recognizes this degron, leading to proteasomal degradation of AR.
- Demonstrated a negative feedback loop regulating AR target genes via this degradation mechanism.
Conclusions:
- Discovered a new mono-ADP-ribosylation-dependent degradation pathway for AR.
- This mechanism provides a new layer of gene regulation for AR target genes.
- Findings offer potential for novel therapeutic strategies targeting AR degradation in prostate cancer.
More Related Videos
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Related Concept Videos
Negative Regulator Molecules
GPCRs Regulate Adenylyl Cylase Activity
Amplifying Signals via Enzymatic Cascade
PI3K/mTOR/AKT Signaling Pathway
GPCR Desensitization
Abnormal Proliferation